DUBLIN, February 2, 2022 (Newswire.com) - Aalto Bio Reagents ltd., a leading developer of critical raw materials and reagents for the development of diagnostic tests, globally announced today that its Sars-Cov-1 spike protein S1 domain is now built. Aalto Bio has set out to develop a full suite of Coronavirus proteins for past, present and future disease outbreaks including Sars-Cov1, Sars-Cov2 and Mers-Cov.
From the start of this COVID-19 pandemic in January 2020, Aalto bio has supported over 120 global diagnostic companies and vaccine developers to build tests for COVID-19 with critical raw materials for the CV-19 virus detection which has enabled frontline testing using multiples of millions of diagnostic tests. In February 2020, Aalto bio began offering its first nucleocapsid COVID-19 protein soon after the Wuhan strain of the virus became known. In April this was followed by our new COVID-19 Lysis buffer reagent for pre-treating COVID-19 samples prior to testing and then in late April our monoclonals. The early availability of our COVID 19 proteins and mabs has helped diagnostic manufacturers and vaccine developers alike build high quality assays with our critical raw materials to faster determine the clinical status of COVID-19.
"Aalto Bio Reagents ltd. remain on hand to help our diagnostic manufacturing partners and vaccine developers around the globe meet their emerging disease diagnostic testing requirements as new variants emerge. Globally we will continue to build new critical materials as we have done since the outset of this world health crisis by delivering first-in-class critical raw material products during this pandemic. With the addition of this new Sars-Cov-1 S1 domain protein, we are looking to collaborate with infectious disease scientists around the globe and will offer the first 3 scientists free material to conduct research on Sars cov1 samples. If you are an early stage or late stage emerging disease scientist interested to collaborate please contact our discovery team at details listed below," stated Philip Noone, CEO Aalto Bio.
About Aalto Bio Reagents
Founded in 1978, Aalto Bio Reagents is a leading developer and provider of raw materials to the in-vitro diagnostics industry and to research laboratories globally. We serve the largest multinational companies in our industry with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-vitro diagnostic application.
Since the company's inception, we have built strong working relationships with our clients who trust us to provide them with the highest quality raw materials to meet the exacting standards of their own product development requirements. Headquartered in Dublin, Ireland, the company is rapidly expanding both its product portfolio and customer base. For further information please visit http://www.aaltobioreagents.com
Source: Aalto Bio Reagents ltd.